Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats via Activation of SIRT3/AMPK/ACC Pathway

Abstract

This study aimed to verify the effects of berberine (BBR) on the fat metabolism proteins involved in the sirtuin 3 (SIRT3)/adenosine 5’-monophosphate (AMP)-activated protein kinase (AMPK)/acetyl-CoA carboxylase (ACC) pathway in the liver tissues of rats with high-fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD). Forty-eight rats were randomly divided into the normal control (NC) group, HFD group or BBR group, with 16 rats in each group. After 8 and 16 weeks of treatment, serum and liver samples were collected. Subsequently, body parameters, biochemical parameters and liver pathology were examined. The expression levels of proteins involved in the SIRT3/AMPK/ACC pathway in the liver were detected by Western blotting. After 8 and 16 weeks of a HFD, the successful establishment of rat models with different degrees of NAFLD was confirmed by hematoxylin and eosin (H&E) and Oil Red O staining. NAFLD rat models exhibited obesity and hyperlipidemia, and the protein expression levels of SIRT3, p-AMPK, p-ACC, and CPT-1A in the liver were significantly decreased compared to those in the NC group. The concurrent administration of BBR with the HFD effectively improved serum and liver lipid profiles and ameliorated liver injury. Furthermore, the protein expression levels of SIRT3, p-AMPK, p-ACC, and CPT-1A in the liver were significantly increased in the BBR group as compared with those in the HFD group. In conclusion, our data suggest that the mechanism by which BBR ameliorates HFD-induced hepatic steatosis may be related to the activation of the SIRT3/AMPK/ACC pathway in the liver.

Keywords

berberine / non-alcoholic fatty liver disease / sirtuin 3 / lipid metabolism

References

[1] RinellaME. Nonalcoholic Fatty Liver Disease. JAMA, 2015, 313(22): 2263

[2] ArgoCK, CaldwellSH. Epidemiology and natural history of non–alcoholic steatohepatitis. Clin Liver Dis, 2009, 13(4): 511-531

[3] LoombaR, SanyalAJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol, 2013, 10(11): 686-690

[4] FanJG, FarrellGC. Epidemiology of non–alcoholic fatty liver disease in China. J Hepatol, 2009, 50(1): 204-210

[5] AlisiA, MancoM, PaneraN, et al.. Association between type two diabetes and non–alcoholic fatty liver disease in youth. Ann Hepatol, 2009, 8(Suppl1): S44-S50

[6] NassirF, IbdahJA. Role of mitochondria in nonalcoholic fatty liver disease. Int J Mol Sci, 2014, 15(5): 8713-8742

[7] OsborneB, BentleyNL, MontgomeryMK, et al.. The role of mitochondrial sirtuins in health and disease. Free Radical Bio Med, 2016, 100: 164-174

[8] HirscheyMD, ShimazuT, GoetzmanE, et al.. SIRT3 regulates mitochondrial fatty–acid oxidation by reversible enzyme deacetylation. Nature, 2010, 464(7285): 121-125

[9] HirscheyMD, ShimazuT, HuangJY, et al.. SIRT3 regulates mitochondrial protein acetylation and intermediary metabolism. Cold Spring Harb Symp Quant Biol, 2011, 76: 267-277

[10] ShiT, FanGQ, XiaoSD. SIRT3 reduces lipid accumulation via AMPK activation in human hepatic cells. J Dig Dis, 2010, 11(1): 55-62

[11] ZhangSJ, LiYF, WangGE, et al.. Caffeine ameliorates high energy diet–induced hepatic steatosis: sirtuin 3 acts as a bridge in the lipid metabolism pathway. Food Funct, 2015, 6(8): 2578-2587

[12] GeY, ZhangY, LiR, et al.. Berberine regulated Gck, G6pc, Pck1 and Srebp–1c expression and activated AMPactivated protein kinase in primary rat hepatocytes. Int J Biol Sci, 2011, 7(5): 673-684

[13] LeeYS, KimWS, KimKH, et al.. Berberine, a natural plant product, activates AMP–activated protein kinase with beneficial metabolic effects in diabetic and insulinresistant states. Diabetes, 2006, 55(8): 2256-2264

[14] YinJ, GaoZ, LiuD, et al.. Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab, 2008, 294(1): E148-E156

[15] ChangX, YanH, FeiJ, et al.. Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high–fat diet in rats. J Lipid Res, 2010, 51(9): 2504-2515

[16] YanHM, XiaMF, WangY, et al.. Efficacy of Berberine in Patients with Non–Alcoholic Fatty Liver Disease. PLos One, 2015, 10(8): e134172

[17] TeodoroJS, DuarteFV, GomesAP, et al.. Berberine reverts hepatic mitochondrial dysfunction in high–fat fed rats: a possible role for SirT3 activation. Mitochondrion, 2013, 13(6): 637-646

[18] GomesAP, DuarteFV, NunesP, et al.. Berberine protects against high fat diet–induced dysfunction in muscle mitochondria by inducing SIRT1–dependent mitochondrial biogenesis. Biochim Biophys Acta, 2012, 1822(2): 185-195

[19] ZhaoL, CangZ, SunH, et al.. Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease. Bmc Endocr Disord, 2017, 17: 13

[20] GuoT, WooSL, GuoX, et al.. Berberine Ameliorates Hepatic Steatosis and Suppresses Liver and Adipose Tissue Inflammation in Mice with Diet–induced Obesity. Sci Rep, 2016, 6: 22 612

[21] KimWS, LeeYS, ChaSH, et al.. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Am J Physiol Endocrinol Metab, 2009, 296(4): E812-E819

[22] SanchesSC, RamalhoLN, AugustoMJ, et al.. Nonalcoholic Steatohepatitis: A Search for Factual Animal Models. Biomed Res Int, 2015, 2015: 574832

[23] FabbriniE, SullivanS, KleinS. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology, 2010, 51(2): 679-689

[24] CohenJC, HortonJD, HobbsHH. Human fatty liver disease: old questions and new insights. Science, 2011, 332(6037): 1519-1523

[25] Vilar–GomezE, Martinez–PerezY, Calzadilla–BertotL, et al.. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology, 2015, 149(2): 367-378

[26] XieW, GuD, LiJ, et al.. Effects and action mechanisms of berberine and Rhizoma coptidis on gut microbes and obesity in high–fat diet–fed C57BL/6J mice. PLos One, 2011, 6(9): e24520

[27] ChatrathH, VuppalanchiR, ChalasaniN. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis, 2012, 32(1): 22-29

[28] HirscheyMD, ShimazuT, JingE, et al.. SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol Cell, 2011, 44(2): 177-190

[29] WuT, LiuYH, FuYC, et al.. Direct evidence of sirtuin downregulation in the liver of non–alcoholic fatty liver disease patients. Ann Clin Lab Sci, 2014, 44(4): 410-418

[30] HuangYY, GusdonAM, QuS. Nonalcoholic fatty liver disease: molecular pathways and therapeutic strategies. Lipids Health Dis, 2013, 12: 171

[31] KahnBB, AlquierT, CarlingD, et al.. AMP–activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab, 2005, 1(1): 15-25

[32] TeodoroJS, DuarteFV, GomesAP, et al.. Berberine reverts hepatic mitochondrial dysfunction in high–fat fed rats: a possible role for SirT3 activation. Mitochondrion, 2013, 13(6): 637-646

[33] ShuklaS, SharmaA, PandeyVK, et al.. Concurrent acetylation of FoxO1/3a and p53 due to sirtuins inhibition elicit Bim/PUMA mediated mitochondrial dysfunction and apoptosis in berberine–treated HepG2 cells. Toxicol Appl Pharmacol, 2016, 291: 70-83

[34] XuM, XiaoY, YinJ, et al.. Berberine promotes glucose consumption independently of AMP–activated protein kinase activation. PLos One, 2014, 9(7): e103702